Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mary Jo Carden"'
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:904-912
The Biologics Price Competition and Innovation Act (BPCIA) of 2009, which included pathways for FDA approval of biosimilar products, was designed to promote more affordable, expanded patient access to biologic therapies. Achieving these BPCIA goals d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e576f251fed1268f49bbd589d2d278
https://doi.org/10.18553/jmcp.2019.18412
https://doi.org/10.18553/jmcp.2019.18412
Autor:
Joshua Chou, Catherine E. Cooke, Kriti Sharma, Karen Pellegrin, Nicole Brandt, Patty A. Kumbera, Mary Jo Carden
Publikováno v:
Journal of managed carespecialty pharmacy. 25(3)
The Medication Therapy Management (MTM) Program Standardized Format (SF) is a written summary of a comprehensive medication review (CMR) that must be provided to Medicare Part D beneficiaries. Concerns have been raised regarding the number of pages o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0e5cdf4d83c396ecfa7ce75e5715e9
https://pubmed.ncbi.nlm.nih.gov/30816816
https://pubmed.ncbi.nlm.nih.gov/30816816
Autor:
Joel W. Hay, Joan S. McClure, Lori Zablow-Salles, Charlie Dragovich, Daniel C. Malone, Jay Mcknight, Jennifer S. Graff, Eleanor M. Perfetto, Philip Naughten, Lisa Cashman, Terry Richardson, James K. Marttila, Jay Jackson, Soumi Saha, Elizabeth J. Cobbs, Russell Hoverman, Gergana Zlateva, Mary Jo Carden, Carly Rodriguez, Susan C. Winckler, Christopher Michael Blanchette, Craig Mattson, Kevin Bruns, Rhys Williams, Jeffrey Francer, Laurie B. Burke, Peter J. Neumann, Gregory W. Daniel, Laurie Wesolowicz, Susan A. Cantrell, Yanjun Carol Bao, Dan Danielson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:826-831
The Food and Drug Administration Modernization Act (FDAMA) of 1997 included Section 114 as a regulatory safe harbor with the goal of increasing the dissemination of health care economic information (HCEI) to those responsible for formulary decision m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af43d4f555b7ad8b93d1cc8ad36c090
https://doi.org/10.18553/jmcp.2016.22.7.826
https://doi.org/10.18553/jmcp.2016.22.7.826
Autor:
Miller Sb, Motheral B, Chan H, Surratt P, Charlie Dragovich, Marsha A. Raebel, Sega T, Walraven C, Jeffrey S. Brown, Hilbrich L, Gregory W. Daniel, Eichelberger B, Bruns K, Mary Jo Carden, Priddy Sa, Moore T, Randhawa G, Baldziki M, Hendrickson M, White Tj, Cheetham Tc, Rosato E, Conn T, Johnson A
Publikováno v:
Journal of managed carespecialty pharmacy. 21(1)
BACKGROUND The Biologics Price Competition and Innovation Act, introduced as part of the Affordable Care Act, directed the FDA to create an approval pathway for biologic products shown to be biosimilar or interchangeable with an FDA-approved innovato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913cd5d8b2e5419891a5d89525c7dd71
https://pubmed.ncbi.nlm.nih.gov/25562770
https://pubmed.ncbi.nlm.nih.gov/25562770